A Phase 3 interventional study of Ticagrelor and Placebo in Sickle Cell Disease, sponsored by AstraZeneca. Terminated at 55 sites in 16 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-04-09.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.
Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one is the 10th largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2018, is one of 17 in phase 3, and was the 32nd registered.
104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.
Browse Vaso-Occlusive Crises studies →13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18–88
Mohsen Saidinejad · Sites in United States
Ages 5–20
CSL Behring · Sites in United States, Belgium, France and 4 more countries
Ages 18+
CSL Behring · Sites in United States, Turkey, United Kingdom
Ages 12+
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 2 more countries
Ages 12–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 20 · Phase 3 17 · Phase 4 6
First in 2000; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 193 is above the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.
Median enrollment 63 across the 56 interventional studies, 82 across the 4 observational. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 60 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 2 studies filed under Vaso-Occlusive Crises — fewer than ten, so there is no comparison to draw.
3 of the studies in Vaso-Occlusive Crises with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989567Phase 3Asklepion Pharmaceuticals, LLCA Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis | 2027-06 |
| NCT03353584St. Jude Children's Research HospitalEffect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease | 2026-11 |
| NCT06699849CSL BehringSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis | 2027-10-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 60 studies in Vaso-Occlusive Crises with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease
Hestia3 will evaluate the efficacy, safety and tolerability of ticagrelor versus placebo in children with SCD during treatment for at least 12 months and up to approximately 24 months.
104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.
This study's enrollment of 193 is above the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.
Browse Vaso-Occlusive Crises studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Compared within Vaso-Occlusive Crises, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia, Sickle Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female paediatric patients aged ≥2 to \<18 years and body weight of ≥12 kg (at Visit 1), diagnosed with HbSS or HbS/β0 as confirmed by high-performance liquid chromatography or electrophoresis.
Note: Diagnosis of SCD (if not confirmed prior to screening and records available on the medical file) should be confirmed for HbSS or HbS/β0 by high-performance liquid chromatography or haemoglobin electrophoresis, performed at the site's local lab, in order to confirm the type of mutation.
Exclusion Criteria:
Findings on TCD: Current or previous values for time averaged mean of the maximum velocity (TAMMV) that are Conditional or Abnormal. Patients with Conditional TAMMV values or higher (≥153 cm/sec using TCD imaging technique [TCDi] which is corresponding to ≥170 cm/sec by the non-imaging technique). Both the middle cerebral artery and the internal carotid artery should be considered.
Any other criteria that would locally be considered as TCD indications for chronic transfusion would also exclude the patient.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The double-blinded study drug dose will be weight dependent: * ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day * \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day * \>48 kg: Ticagrelor 45 mg, twice a day.
Drug: Ticagrelor
The double-blinded study drug dose will be weight dependent: * ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day * \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day * \>48 kg: Placebo to match ticagrelor 45 mg, twice a day.
Drug: Placebo
The double-blinded study drug dose will be weight dependent: * ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day * \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day * \>48 kg: Ticagrelor 45 mg, twice a day.
The double-blinded study drug dose will be weight dependent: * ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day * \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day * \>48 kg: Placebo to match ticagrelor 45 mg, twice a day.
Number of Vaso-Occlusive Crisis Events
A VOC is the composite of a painful crisis and/or an acute chest syndrome (ACS) event. The number of VOC events is defined as the count of VOC events experienced by a participant throughout the treatment period.
Time frame: From randomization (Day 0) up to end of study (EOS) visit or date of premature study discontinuation, up to approximately 20 months
Number of Painful Crisis Events
A painful crisis is an onset or worsening of pain that lasts at least 2 hours, for which there is no explanation other than vaso-occlusion and which requires therapy with oral or parenteral opioids, parenteral non-steroidal anti-inflammatory drugs, or other analgesics prescribed by a healthcare provider in a medical setting (such as a hospital, clinic or emergency room visit) or at home. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Number of Acute Chest Syndrome Events
The ACS is an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Duration of Painful Crises
The duration of painful crises is defined as the sum of the duration of painful crises experienced by a participant over the defined treatment period. If two or more events have overlapping durations, the overlapping days were counted only once.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Number of Vaso-Occlusive Crisis Events Requiring Hospitalization or Emergency Department Visits
The number of VOC events requiring hospitalization or emergency department visits is defined as the count of VOC events experienced by a participant over the treatment period, for which the primary setting for VOC treatment was in-patient hospitalization or emergency department. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Number of Days Hospitalized for Vaso-Occlusive Crisis Events
The number of days hospitalized for all individual VOC events experienced by a participant during the treatment period is defined as the sum of the duration of all individual hospitalizations (taking into account potential overlapping hospitalization days of VOC components) during VOC events experienced by a participant over the treatment period for which the primary setting for VOC treatment was in-patient hospitalization.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Number of Acute Sickle Cell Disease Complications
The number of acute SCD complications is defined as the count of all individual acute SCD complications experienced by a participant over the treatment period. Acute SCD complications are defined as any one or more of the following individual complications: Transient ischaemic attack/ischaemic stroke, hepatic sequestration, splenic sequestration, priapism, and dactylitis.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Number of Days Hospitalized for Acute Sickle Cell Disease Complications
The number of days hospitalized for acute SCD complications is defined as the sum of the duration of all individual hospitalizations (taking into account potential overlapping hospitalization days) due to acute SCD complications experienced by a participant over the treatment period, for which hospitalization was reported.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Number of Sickle Cell-Related Red Blood Cell (RBC) Transfusions
The number of participants with at least one sickle cell-related RBC transfusion reported. Adverse events resulting in the need for RBC transfusions were captured prior to database lock to determine if the transfusion was sickle cell-related or not.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Health-Related Quality of Life Total Score Using the Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module
The PedsQL SCD module instrument developed using a 5-point Likert scale (where 0= never and 4= almost always) for the participant self-report forms for ages ≥5 to \<8 years, ≥8 to \<13 years, and ≥13 to ≤18 years and the caregiver proxy-report form specific for ≥2 to \<5 years was used. The PedsQL SCD module measures problems in the following categories: * Pain: 3 sub-scales * Worry: 2 sub-scales * Emotions: 1 sub-scale * Treatment: 1 sub-scale * Communication: 2 sub-scales * Total score PedsQL SCD module items were reverse-scored and linearly transformed to a 0 to 100 scale (0= 100, 1= 75, 2= 50, 3= 25, 4= 0) so that higher scores indicate better quality of life. To create the PedsQL SCD module total score (43/42/40 items - depending on version completed) the arithmetic mean of the transformed scores was computed as the sum of the items transformed scores divided by the number of items answered. Baseline values are the closest observation prior to and including the randomization visit.
Time frame: For ages ≥2 to <5 years and ≥5 to <8 years: Baseline (observation prior to and including the randomization visit) and Months 6, and 12; For ages ≥8 to <13 years and ≥13 to ≤18 years: Baseline and Months 6, 12, and 18
Fatigue Total Score Using Pediatric Quality of Life Inventory Multidimensional Fatigue Scale
The PedsQL multidimensional fatigue scale instrument developed using a 5-point Likert scale (where 0= never and 4= almost always) for the participant self-report forms for ages ≥5 to \<8 years, ≥8 to \<13 years, and ≥13 to ≤18 years and the caregiver proxy-report form specific for ≥2 to \<5 years was used. The PedsQL multidimensional fatigue scale measures problems in the following categories: * General (6 items) * Sleep/rest (6 items) * Cognitive fatigue (6 items) * Total score (18 items) PedsQL multidimensional fatigue scale items were reverse-scored and linearly transformed to a 0 to 100 scale (0= 100, 1= 75, 2= 50, 3= 25, 4= 0) so that higher scores indicate better quality of life. To create the PedsQL multidimensional fatigue scale total score (18 items), the arithmetic mean of the transformed scores was computed as the sum of the items transformed scores divided by the number of items answered. Baseline values are closest observation prior to and including randomization visit.
Time frame: For ages ≥2 to <5 years and ≥5 to <8 years: Baseline (observation prior to and including the randomization visit) and Months 6, and 12; For ages ≥8 to <13 years and ≥13 to ≤18 years: Baseline and Months 6, 12, and 18
Percentage of Days of Absence From School or Work Due to Sickle Cell Disease
For participants attending school/work at randomization, absence from school/work due to SCD was recorded weekly by the participant in the eDevice with the help of the caregiver if needed. The percentage of days absent from school/work due to SCD in the defined treatment period was calculated as follows: Percentage of absent days = (total number of days reported)/(total number of questionnaires answered ×7).
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants <5 Years of Age
The Face, Legs, Activity, Cry, Consolability (FLACC) scale is caregiver-reported and used to assess pain daily during the VOC event for those participants \<5 years of age as determined at randomization. Each of the 5 behaviours observed are assigned a score of 0, 1 or 2. The total FLACC score ranges between 0 and 10, with 0 representing "no pain" and 10 representing "very much pain". Lower score indicate better outcome. Worst pain ratings were collected once daily throughout the duration of the VOC event using an eDevice.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants ≥5 Years of Age
The Faces Pain Scale-revised (FPS-R) was administered to assess pain daily during the VOC event by those participants aged ≥5 years as determined at randomization. The FPS-R consists of 6 faces and scoring ranges between 0 and 10 (with an increase in numeric value by 2), where 0 is "no pain" and 10 is "very much pain". Lower score indicate better outcome. Worst pain ratings were collected once daily throughout the duration of the VOC event using an eDevice.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Type of Analgesics Used by Participants During Vaso-Occlusive Crisis Events
Analgesics use (opioid and non-opioid) during VOC events.
Time frame: From randomization (Day 0) up to EOS visit or date of premature study discontinuation, up to approximately 20 months
Palatability of the Study Treatment Assessed by Study Medication Palatability Assessment (SMPA) in Participants ≤4 Years of Age
Response to palatability was assessed through the SMPA question "Was any behaviour observed when the study medication was given to this participant that would be indicative of a negative response to the palatability of the study medication?". This was presented as a binary outcome (that is, where "No" is no negative response and "Yes" is negative response). No negative response was considered as a positive outcome.
Time frame: Baseline (randomization visit) and Month 6
Swallowability of the Study Treatment Assessed by Study Medication Palatability Assessment in Participants ≤4 Years of Age
An observer's assessment of the participant's behaviour using the SMPA was performed for all participants taking the study treatment who are 2 to 4 years of age. Willingness to swallow was assessed and categorized as follows: * Swallowed without a problem * Some resistance but did swallow * Spit out some/all of the medication * Vomited up the medication. The category "swallowed without a problem" was considered as positive outcome.
Time frame: Baseline (randomization visit) and Month 6
Palatability of the Study Treatment Assessed by Facial Hedonic Scale (FHS) in Participants ≥5 Years of Age
The FHS method was used for all participants taking the study treatment who are ≥5 years of age. The FHS consists of 5 faces with descriptions ranging from "Dislike very much" to "Like very much". The face with description "Like very much" was considered as positive outcome. The way in which the study treatment was taken, that is, whether the tablet is whole or dispersed, was captured.
Time frame: Baseline (randomization visit) and Month 6
This Phase III study was conducted in pediatric participants with sickle cell disease (SCD) at 53 sites in 16 countries (Kenya, India, Uganda, Egypt, Lebanon, Ghana, South Africa, Tanzania, United Kingdom, Turkey, Spain, Italy, Belgium, Greece, Brazil and United States) between 26 September 2018 and 13 August 2020.
| Milestone | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Started | 101 | 92 |
| Received treatment | 101 | 92 |
| Completed | 0 | 0 |
| Not completed | 101 | 92 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Death | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Randomized in error | 1 | 0 |
| Withdrew: Study termination by sponsor | 94 | 86 |
A VOC is the composite of a painful crisis and/or an acute chest syndrome (ACS) event. The number of VOC events is defined as the count of VOC events experienced by a participant throughout the treatment period.
| VOC events | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Number of Vaso-Occlusive Crisis Events | 249 | 202 |
A painful crisis is an onset or worsening of pain that lasts at least 2 hours, for which there is no explanation other than vaso-occlusion and which requires therapy with oral or parenteral opioids, parenteral non-steroidal anti-inflammatory drugs, or other analgesics prescribed by a healthcare provider in a medical setting (such as a hospital, clinic or emergency room visit) or at home. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.
| painful crisis events | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Number of Painful Crisis Events | 248 | 209 |
The ACS is an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.
| ACS events | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Number of Acute Chest Syndrome Events | 6 | 6 |
The duration of painful crises is defined as the sum of the duration of painful crises experienced by a participant over the defined treatment period. If two or more events have overlapping durations, the overlapping days were counted only once.
| days | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Duration of Painful Crises | 1476 | 1441 |
The number of VOC events requiring hospitalization or emergency department visits is defined as the count of VOC events experienced by a participant over the treatment period, for which the primary setting for VOC treatment was in-patient hospitalization or emergency department. Events with an onset date \<=7 days of the previous event onset date are not counted as new events.
| VOC events requiring hospitalization | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Number of Vaso-Occlusive Crisis Events Requiring Hospitalization or Emergency Department Visits | 87 | 51 |
The number of days hospitalized for all individual VOC events experienced by a participant during the treatment period is defined as the sum of the duration of all individual hospitalizations (taking into account potential overlapping hospitalization days of VOC components) during VOC events experienced by a participant over the treatment period for which the primary setting for VOC treatment was in-patient hospitalization.
| days | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Number of Days Hospitalized for Vaso-Occlusive Crisis Events | 526 | 256 |
The number of acute SCD complications is defined as the count of all individual acute SCD complications experienced by a participant over the treatment period. Acute SCD complications are defined as any one or more of the following individual complications: Transient ischaemic attack/ischaemic stroke, hepatic sequestration, splenic sequestration, priapism, and dactylitis.
| acute SCD complications | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Number of Acute Sickle Cell Disease Complications | 6 | 3 |
The number of days hospitalized for acute SCD complications is defined as the sum of the duration of all individual hospitalizations (taking into account potential overlapping hospitalization days) due to acute SCD complications experienced by a participant over the treatment period, for which hospitalization was reported.
| days | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Number of Days Hospitalized for Acute Sickle Cell Disease Complications | 0 | 6 |
The number of participants with at least one sickle cell-related RBC transfusion reported. Adverse events resulting in the need for RBC transfusions were captured prior to database lock to determine if the transfusion was sickle cell-related or not.
| RBC transfusions | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Number of Sickle Cell-Related Red Blood Cell (RBC) Transfusions | 39 | 49 |
The PedsQL SCD module instrument developed using a 5-point Likert scale (where 0= never and 4= almost always) for the participant self-report forms for ages ≥5 to \<8 years, ≥8 to \<13 years, and ≥13 to ≤18 years and the caregiver proxy-report form specific for ≥2 to \<5 years was used. The PedsQL SCD module measures problems in the following categories: * Pain: 3 sub-scales * Worry: 2 sub-scales * Emotions: 1 sub-scale * Treatment: 1 sub-scale * Communication: 2 sub-scales * Total score PedsQL SCD module items were reverse-scored and linearly transformed to a 0 to 100 scale (0= 100, 1= 75, 2= 50, 3= 25, 4= 0) so that higher scores indicate better quality of life. To create the PedsQL SCD module total score (43/42/40 items - depending on version completed) the arithmetic mean of the transformed scores was computed as the sum of the items transformed scores divided by the number of items answered. Baseline values are the closest observation prior to and including the randomization visit.
| score on a scale | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| >=2 to <5 years: Baseline | 88.81 ± 14.107 | 67.02 ± 20.041 |
| >=2 to <5 years: Month 6 | 80.75 ± 20.779 | 81.37 ± 14.125 |
| >=2 to <5 years: Month 12 | — | 88.10 ± NA |
| >=5 to <8 years: Baseline | 75.05 ± 20.147 | 74.04 ± 21.646 |
| >=5 to <8 years: Month 6 | 83.04 ± 15.332 | 84.91 ± 18.117 |
| >=5 to <8 years: Month 12 | 65.63 ± 48.614 | 97.50 ± NA |
| >=8 to <13 years: Baseline | 62.35 ± 24.725 | 67.98 ± 24.338 |
| >=8 to <13 years: Month 6 | 76.52 ± 17.189 | 75.76 ± 21.749 |
| >=8 to <13 years: Month 12 | 83.20 ± 13.479 | 64.12 ± 27.253 |
| >=8 to <13 years: Month 18 | 86.05 ± NA | — |
| >=13 to <=18 years: Baseline | 64.45 ± 18.746 | 60.81 ± 24.979 |
| >=13 to <=18 years: Month 6 | 68.13 ± 16.811 | 74.42 ± 19.146 |
| >=13 to <=18 years: Month 12 | 63.05 ± 19.810 | 73.26 ± 22.589 |
| >=13 to <=18 years: Month 18 | 65.12 ± NA | — |
The PedsQL multidimensional fatigue scale instrument developed using a 5-point Likert scale (where 0= never and 4= almost always) for the participant self-report forms for ages ≥5 to \<8 years, ≥8 to \<13 years, and ≥13 to ≤18 years and the caregiver proxy-report form specific for ≥2 to \<5 years was used. The PedsQL multidimensional fatigue scale measures problems in the following categories: * General (6 items) * Sleep/rest (6 items) * Cognitive fatigue (6 items) * Total score (18 items) PedsQL multidimensional fatigue scale items were reverse-scored and linearly transformed to a 0 to 100 scale (0= 100, 1= 75, 2= 50, 3= 25, 4= 0) so that higher scores indicate better quality of life. To create the PedsQL multidimensional fatigue scale total score (18 items), the arithmetic mean of the transformed scores was computed as the sum of the items transformed scores divided by the number of items answered. Baseline values are closest observation prior to and including randomization visit.
| score on a scale | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| >=2 to <5 years: Baseline | 88.06 ± 16.304 | 70.56 ± 23.220 |
| >=2 to <5 years: Month 6 | 84.44 ± 15.541 | 81.94 ± 22.775 |
| >=2 to <5 years: Month 12 | — | 94.44 ± NA |
| >=5 to <8 years: Baseline | 82.33 ± 11.450 | 84.13 ± 16.139 |
| >=5 to <8 years: Month 6 | 87.12 ± 10.553 | 87.70 ± 16.076 |
| >=5 to <8 years: Month 12 | 95.83 ± 5.893 | 100.00 ± NA |
| >=8 to <13 years: Baseline | 64.72 ± 26.779 | 69.51 ± 25.261 |
| >=8 to <13 years: Month 6 | 75.65 ± 18.571 | 77.89 ± 22.283 |
| >=8 to <13 years: Month 12 | 81.48 ± 17.866 | 65.87 ± 25.495 |
| >=8 to <13 years: Month 18 | 73.61 ± NA | — |
| >=13 to <=18 years: Baseline | 68.06 ± 21.781 | 67.17 ± 18.223 |
| >=13 to <=18 years: Month 6 | 73.53 ± 19.138 | 75.21 ± 14.913 |
| >=13 to <=18 years: Month 12 | 67.13 ± 22.556 | 60.28 ± 23.664 |
| >=13 to <=18 years: Month 18 | 72.22 ± NA | — |
For participants attending school/work at randomization, absence from school/work due to SCD was recorded weekly by the participant in the eDevice with the help of the caregiver if needed. The percentage of days absent from school/work due to SCD in the defined treatment period was calculated as follows: Percentage of absent days = (total number of days reported)/(total number of questionnaires answered ×7).
| percentage of days | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Percentage of Days of Absence From School or Work Due to Sickle Cell Disease | 5.24 ± 8.942 | 4.24 ± 4.964 |
The Face, Legs, Activity, Cry, Consolability (FLACC) scale is caregiver-reported and used to assess pain daily during the VOC event for those participants \<5 years of age as determined at randomization. Each of the 5 behaviours observed are assigned a score of 0, 1 or 2. The total FLACC score ranges between 0 and 10, with 0 representing "no pain" and 10 representing "very much pain". Lower score indicate better outcome. Worst pain ratings were collected once daily throughout the duration of the VOC event using an eDevice.
| score on a scale | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants <5 Years of Age | 3.4 ± 2.51 | 2.9 ± 1.99 |
The Faces Pain Scale-revised (FPS-R) was administered to assess pain daily during the VOC event by those participants aged ≥5 years as determined at randomization. The FPS-R consists of 6 faces and scoring ranges between 0 and 10 (with an increase in numeric value by 2), where 0 is "no pain" and 10 is "very much pain". Lower score indicate better outcome. Worst pain ratings were collected once daily throughout the duration of the VOC event using an eDevice.
| score on a scale | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants ≥5 Years of Age | 4.5 ± 2.71 | 4.1 ± 2.02 |
Analgesics use (opioid and non-opioid) during VOC events.
| participants | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Opioids: Yes | 46 | 22 |
| Opioids: No | 57 | 50 |
| Non-opioids: Yes | 69 | 57 |
| Non-opioids: No | 14 | 7 |
Response to palatability was assessed through the SMPA question "Was any behaviour observed when the study medication was given to this participant that would be indicative of a negative response to the palatability of the study medication?". This was presented as a binary outcome (that is, where "No" is no negative response and "Yes" is negative response). No negative response was considered as a positive outcome.
| Participants | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Baseline: Whole tablet — Negative response to palatability - No | 5 | 8 |
| Baseline: Whole tablet — Negative response to palatability - Yes | 0 | 0 |
| Baseline: Dispersed tablet — Negative response to palatability - No | 1 | 2 |
| Baseline: Dispersed tablet — Negative response to palatability - Yes | 0 | 0 |
| Month 6: Whole tablet — Negative response to palatability - No | 4 | 9 |
| Month 6: Whole tablet — Negative response to palatability - Yes | 0 | 0 |
| Month 6: Dispersed tablet — Negative response to palatability - No | 1 | 1 |
| Month 6: Dispersed tablet — Negative response to palatability - Yes | 0 | 0 |
An observer's assessment of the participant's behaviour using the SMPA was performed for all participants taking the study treatment who are 2 to 4 years of age. Willingness to swallow was assessed and categorized as follows: * Swallowed without a problem * Some resistance but did swallow * Spit out some/all of the medication * Vomited up the medication. The category "swallowed without a problem" was considered as positive outcome.
| Participants | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Baseline: Whole tablet — Swallow without problem | 5 | 8 |
| Baseline: Whole tablet — Some resistance but did swallow | 0 | 0 |
| Baseline: Whole tablet — Spit out some/all medication | 0 | 0 |
| Baseline: Whole tablet — Vomited up medication | 0 | 0 |
| Baseline: Dispersed tablet — Swallow without problem | 1 | 2 |
| Baseline: Dispersed tablet — Some resistance but did swallow | 0 | 0 |
| Baseline: Dispersed tablet — Spit out some/all medication | 0 | 0 |
| Baseline: Dispersed tablet — Vomited up medication | 0 | 0 |
| Month 6: Whole tablet — Swallow without problem | 4 | 9 |
| Month 6: Whole tablet — Some resistance but did swallow | 0 | 0 |
| Month 6: Whole tablet — Spit out some/all medication | 0 | 0 |
| Month 6: Whole tablet — Vomited up medication | 0 | 0 |
| Month 6: Dispersed tablet — Swallow without problem | 1 | 1 |
| Month 6: Dispersed tablet — Some resistance but did swallow | 0 | 0 |
| Month 6: Dispersed tablet — Spit out some/all medication | 0 | 0 |
| Month 6: Dispersed tablet — Vomited up medication | 0 | 0 |
The FHS method was used for all participants taking the study treatment who are ≥5 years of age. The FHS consists of 5 faces with descriptions ranging from "Dislike very much" to "Like very much". The face with description "Like very much" was considered as positive outcome. The way in which the study treatment was taken, that is, whether the tablet is whole or dispersed, was captured.
| Participants | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Baseline: Whole tablet — Dislike very much | 3 | 2 |
| Baseline: Whole tablet — Dislike a little | 4 | 2 |
| Baseline: Whole tablet — Not sure | 12 | 8 |
| Baseline: Whole tablet — Like a little | 25 | 23 |
| Baseline: Whole tablet — Like very much | 48 | 45 |
| Baseline: Dispersed tablet — Dislike very much | 0 | 0 |
| Baseline: Dispersed tablet — Dislike a little | 0 | 0 |
| Baseline: Dispersed tablet — Not sure | 1 | 0 |
| Baseline: Dispersed tablet — Like a little | 0 | 1 |
| Baseline: Dispersed tablet — Like very much | 0 | 1 |
| Month 6: Whole tablet — Dislike very much | 0 | 0 |
| Month 6: Whole tablet — Dislike a little | 5 | 3 |
| Month 6: Whole tablet — Not sure | 4 | 4 |
| Month 6: Whole tablet — Like a little | 30 | 20 |
| Month 6: Whole tablet — Like very much | 44 | 47 |
| Month 6: Dispersed tablet — Dislike very much | 0 | — |
| Month 6: Dispersed tablet — Dislike a little | 0 | — |
| Month 6: Dispersed tablet — Not sure | 1 | — |
| Month 6: Dispersed tablet — Like a little | 0 | — |
| Month 6: Dispersed tablet — Like very much | 0 | — |
Collected over From first dose of study treatment (Day 0) up to 7 days after last dose of study treatment, approximately 20 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ticagrelor 15/30/45 mg bd | 3/100 (3%) | 44/100 (44%) | 82/100 (82%) |
| Placebo | 1/92 (1.1%) | 29/92 (31.5%) | 71/92 (77.2%) |
| Event | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 39/100 | 24/92 |
| AnaemiaBlood and lymphatic system disorders | 6/100 | 7/92 |
| SepsisInfections and infestations | 6/100 | 1/92 |
| MalariaInfections and infestations | 4/100 | 1/92 |
| PneumoniaInfections and infestations | 4/100 | 0/92 |
| HypersplenismBlood and lymphatic system disorders | 0/100 | 3/92 |
| PyrexiaGeneral disorders | 2/100 | 3/92 |
| CellulitisInfections and infestations | 3/100 | 0/92 |
| InfluenzaInfections and infestations | 0/100 | 2/92 |
| ConstipationGastrointestinal disorders | 2/100 | 0/92 |
| Event | Ticagrelor 15/30/45 mg bd | Placebo |
|---|---|---|
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 60/100 | 49/92 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 28/100 | 23/92 |
| Upper respiratory tract infectionInfections and infestations | 19/100 | 24/92 |
| HeadacheNervous system disorders | 24/100 | 18/92 |
| Back painMusculoskeletal and connective tissue disorders | 21/100 | 12/92 |
| CoughRespiratory, thoracic and mediastinal disorders | 17/100 | 7/92 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/100 | 14/92 |
| Abdominal painGastrointestinal disorders | 15/100 | 10/92 |
| MalariaInfections and infestations | 12/100 | 7/92 |
| PyrexiaGeneral disorders | 11/100 | 10/92 |
The Full Analysis Set (FAS) included all randomized participants regardless of treatment received.
| Age, Continuous(years) | Ticagrelor 15/30/45 mg bd | Placebo | Total |
|---|---|---|---|
| Mean | 10.40 ± 4.128 | 10.12 ± 3.799 | 10.26 ± 3.967 |
| Age, Customized(Participants) | Ticagrelor 15/30/45 mg bd | Placebo | Total |
|---|---|---|---|
| ≥2 to <12 years | 61 | 54 | 115 |
| >=12 to <18 years | 40 | 38 | 78 |
| Sex: Female, Male(Participants) | Ticagrelor 15/30/45 mg bd | Placebo | Total |
|---|---|---|---|
| Female | 48 | 43 | 91 |
| Male | 53 | 49 | 102 |
| Race/Ethnicity, Customized(Participants) | Ticagrelor 15/30/45 mg bd | Placebo | Total |
|---|---|---|---|
| White | 25 | 21 | 46 |
| Black or African American | 60 | 51 | 111 |
| Asian | 15 | 15 | 30 |
| Other | 1 | 5 | 6 |
| Race/Ethnicity, Customized(Participants) | Ticagrelor 15/30/45 mg bd | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 5 | 12 |
| Not Hispanic or Latino | 94 | 87 | 181 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Sep 2018 to primary completion in Aug 2020, 22 months.
Results were first posted in Apr 2021, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor